Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate panel hears evidence and concerns as sponsors seek psilocybin advisory board, not legalization
Summary
House Bill 1809 would create a medical psilocybin advisory board to study feasibility for treatment-resistant depression, PTSD and substance use disorders. Supporters cited emerging trial data and veteran interest; opponents warned about Schedule I federal constraints and safety concerns in Colorado and Oregon programs.
Representative (prime sponsor) told the Senate Health and Human Services Committee that House Bill 1809 establishes a medical psilocybin advisory board to study whether a state pathway for therapeutic psilocybin could be designed safely and lawfully. The sponsor emphasized the bill does not legalize possession or recreational use and that the board’s work would be contingent on funding and federal constraints.
Clinical evidence and proponents: Dr. John Teal, a board-certified psychiatrist, summarized recent…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
